Summary
Pfizer Inc. (PFE) filed an 8-K on October 29, 2013, to report its financial results for the third quarter of 2013. The core of this filing is the press release attached as Exhibit 99, which details the company's performance during the period. Investors should note that this report primarily serves to formally incorporate the Q3 2013 earnings announcement into the SEC's public record, rather than providing new operational or strategic disclosures within the 8-K itself. The key information for investors would be found within the referenced press release, which would contain specific figures on revenue, earnings per share (EPS), and potentially commentary on key products or business segments. This filing indicates that Pfizer met its reporting obligations by submitting these results, allowing stakeholders to review the company's financial standing and performance for the third quarter of 2013.
Key Highlights
- 1Pfizer Inc. reported its third quarter 2013 financial results via an 8-K filing on October 29, 2013.
- 2The filing's primary content is a press release (Exhibit 99) announcing the Q3 2013 financial performance.
- 3This 8-K serves to officially file the Q3 2013 earnings press release with the SEC.
- 4Investors can find detailed Q3 2013 financial data, including revenue and EPS, within the referenced press release.
- 5The report does not contain new operational details beyond what is presented in the earnings release.